Margaret T. Kasner
Advanced in Acute Monoblastic Leukemia (AmoL)

Dr. Margaret T. Kasner

Hematology Oncology | Oncology | Palliative Medicine
Jefferson Health
Jefferson Cancer - Honickman Center
1101 Chestnut Street, Floor 14, 
Philadelphia, PA 
Accepting New Patients
Offers Telehealth
22 Years of Experience
Advanced in Acute Monoblastic Leukemia (AmoL)
Jefferson Health
Jefferson Cancer - Honickman Center
1101 Chestnut Street, Floor 14, 
Philadelphia, PA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Margaret Kasner is an Oncologist and a Palliative Medicine provider in Philadelphia, Pennsylvania. Dr. Kasner has been practicing medicine for over 22 years and is rated as an Advanced provider by MediFind in the treatment of Acute Monoblastic Leukemia (AmoL). Her top areas of expertise are Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, Myelodysplastic Syndrome (MDS), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Kasner is currently accepting new patients.

Her clinical research consists of co-authoring 42 peer reviewed articles and participating in 14 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has participated in 1 clinical trial in the study of Acute Monoblastic Leukemia (AmoL).

Graduate Institution
Perelman School Of Medicine At The University Of Pennsylvania
Residency
Hospital of the University of Pennsylvania
Specialties
Hematology Oncology
Oncology
Palliative Medicine
Licenses
Internal Medicine in PA
Board Certifications
Medical Oncology
Hematology
Fellowships
Hospital of the University of Pennsylvania
Hospital Affiliations
Thomas Jefferson University Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Geisinger
  • HMO
  • POS
  • PPO
Health Partners Plans
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
PA Health and Wellness
  • HMO
  • MANAGED MEDICAID PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

Jefferson Cancer - Honickman Center
1101 Chestnut Street, Floor 14, Philadelphia, PA 19107
Call: 215-955-8874

Additional Areas of Focus

Dr. Kasner has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Aplastic Anemia

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

Post Transplant Cyclophosphamide for Unrelated and Related Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancies
Post Transplant Cyclophosphamide for Unrelated and Related Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancies
Enrollment Status: Completed
Publish Date: December 15, 2025
Intervention Type: Drug, Radiation, Genetic
Study Phase: Phase 2
A Phase II Study of Azacitidine and Sirolimus for the Treatment of High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Refractory to or Not Eligible for Intensive Chemotherapy
A Phase II Study of Azacitidine and Sirolimus for the Treatment of High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Refractory to or Not Eligible for Intensive Chemotherapy
Enrollment Status: Completed
Publish Date: December 10, 2025
Intervention Type: Drug
Study Drugs: Sirolimus, Azacitidine
Study Phase: Phase 2
A Two Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Hematologic Malignancies
A Two Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Hematologic Malignancies
Enrollment Status: Completed
Publish Date: October 30, 2025
Intervention Type: Drug, Radiation, Procedure, Other, Biological
Study Drugs: Fludarabine, Thiotepa, Cyclophosphamide, Tacrolimus, Mycophenolate Mofetil, Allogeneic Lymphocytes
Study Phase: Phase 2
A Phase I Trial of Palbociclib in Combination With Dexamethasone in Relapsed or Refractory Adult B-Cell Acute Lymphoblastic Leukemia (ALL)
A Phase I Trial of Palbociclib in Combination With Dexamethasone in Relapsed or Refractory Adult B-Cell Acute Lymphoblastic Leukemia (ALL)
Enrollment Status: Completed
Publish Date: May 15, 2025
Intervention Type: Drug
Study Drugs: Palbociclib, Dexamethasone
Study Phase: Phase 1
A Two-Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Advanced Cutaneous T Cell Lymphoma
A Two-Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Advanced Cutaneous T Cell Lymphoma
Enrollment Status: Withdrawn
Publish Date: May 02, 2025
Intervention Type: Drug, Radiation, Biological, Procedure
Study Phase: Phase 1
Phase I/II Study of Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide for Refractory or Relapsed Aggressive B-cell Lymphomas
Phase I/II Study of Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide for Refractory or Relapsed Aggressive B-cell Lymphomas
Enrollment Status: Completed
Publish Date: April 30, 2025
Intervention Type: Drug, Procedure, Genetic
Study Drugs: Bendamustine, Ofatumumab, Carboplatin, Etoposide
Study Phase: Phase 1/Phase 2
A Two Step Approach to Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematologic Malignancies Using One Haploidentical Donor
A Two Step Approach to Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematologic Malignancies Using One Haploidentical Donor
Enrollment Status: Completed
Publish Date: April 30, 2025
Intervention Type: Drug, Biological, Procedure, Radiation
Study Phase: Phase 2
A Two Step Approach To Matched-Sibling Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematological Malignancies
A Two Step Approach To Matched-Sibling Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematological Malignancies
Enrollment Status: Completed
Publish Date: April 30, 2025
Intervention Type: Device
Study Phase: Phase 2
A Pilot, Pharmacodynamic Correlate Trial of Sirolimus in Combination With Chemotherapy (Idarubicin, Cytarabine) for the Treatment of Newly Diagnosed Acute Myelogenous Leukemia
A Pilot, Pharmacodynamic Correlate Trial of Sirolimus in Combination With Chemotherapy (Idarubicin, Cytarabine) for the Treatment of Newly Diagnosed Acute Myelogenous Leukemia
Enrollment Status: Completed
Publish Date: April 29, 2025
Intervention Type: Drug
Study Phase: Early Phase 1
A Two Step Approach to Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies
A Two Step Approach to Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies
Enrollment Status: Completed
Publish Date: April 24, 2025
Intervention Type: Drug, Radiation, Other, Biological, Procedure
Study Drugs: Fludarabine, T Cell-Depleted Donor Lymphocyte Infusion, Cyclophosphamide, Tacrolimus, Mycophenolate mofetil
Study Phase: Phase 2
A Phase 2, Open-Label Study of BGB-A317 in Patients With Relapsed or Refractory Mature T- and NK-cell Neoplasms
A Phase 2, Open-Label Study of BGB-A317 in Patients With Relapsed or Refractory Mature T- and NK-cell Neoplasms
Enrollment Status: Completed
Publish Date: October 26, 2024
Intervention Type: Drug
Study Drug: Tislelizumab
Study Phase: Phase 2
A Phase I/II Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Efficacy of ONO-7475 in Patients With Acute Leukemias or Myelodysplastic Syndromes
A Phase I/II Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Efficacy of ONO-7475 in Patients With Acute Leukemias or Myelodysplastic Syndromes
Enrollment Status: Terminated
Publish Date: July 15, 2024
Intervention Type: Drug
Study Drugs: ONO-7475, Venetoclax
Study Phase: Phase 1/Phase 2
A Biomarker Validation Study to Establish Whether Serial Flow Cytometric Measurements Predict Clinical Response to Sirolimus and MEC (Mitoxantrone Etoposide Cytarabine) Treatment in Patients With High-Risk Acute Myelogenous Leukemia
A Biomarker Validation Study to Establish Whether Serial Flow Cytometric Measurements Predict Clinical Response to Sirolimus and MEC (Mitoxantrone Etoposide Cytarabine) Treatment in Patients With High-Risk Acute Myelogenous Leukemia
Enrollment Status: Completed
Publish Date: October 10, 2023
Intervention Type: Drug
Study Drugs: Sirolimus, Mitoxantrone, Etoposide, Cytarabine
Study Phase: Phase 2
A Two Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies
A Two Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies
Enrollment Status: Completed
Publish Date: November 17, 2022
Intervention Type: Radiation, Drug, Biological, Device, Procedure
Study Drugs: Fludarabine, Busulfan, Cyclophosphamide, Tacrolimus, Mycophenolate Mofetil, Donor Lymphocyte Infusion
Study Phase: Phase 2
View 13 Less Clinical Trials

42 Total Publications

Anexelekto (Axl)/Mer inhibitor tamnorzatinib in patients with relapsed/refractory acute myeloid leukaemia: Results from a phase I (monotherapy) and phase II (combination with venetoclax) clinical study.
Anexelekto (Axl)/Mer inhibitor tamnorzatinib in patients with relapsed/refractory acute myeloid leukaemia: Results from a phase I (monotherapy) and phase II (combination with venetoclax) clinical study.
Journal: Acta haematologica
Published: April 10, 2025
View All 42 Publications
Similar Doctors
Distinguished in Acute Monoblastic Leukemia (AmoL)
Dr. Dale G. Schaar
Oncology
Distinguished in Acute Monoblastic Leukemia (AmoL)
Dr. Dale G. Schaar
Oncology

Rutgers Health-Rwj Scleroderma Program

195 Little Albany St, 
New Brunswick, NJ 
 (53.1 miles away)
732-235-2465
Languages Spoken:
English
See accepted insurances

Dale Schaar is an Oncologist in New Brunswick, New Jersey. Dr. Schaar is rated as a Distinguished provider by MediFind in the treatment of Acute Monoblastic Leukemia (AmoL). His top areas of expertise are Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, Acute Lymphoblastic Leukemia (ALL), and Bone Marrow Aspiration.

Advanced in Acute Monoblastic Leukemia (AmoL)
Dr. Henry H. Fung
Hematology Oncology | Hematology | Oncology
Advanced in Acute Monoblastic Leukemia (AmoL)
Dr. Henry H. Fung
Hematology Oncology | Hematology | Oncology

Temple Faculty Practice Plan Inc

3401 N Broad St, 
Philadelphia, PA 
 (3.8 miles away)
215-707-5030
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Henry Fung is a Hematologist Oncology specialist and a Hematologist in Philadelphia, Pennsylvania. Dr. Fung is rated as a Distinguished provider by MediFind in the treatment of Acute Monoblastic Leukemia (AmoL). His top areas of expertise are Hodgkin Lymphoma, Classical Hodgkin Lymphoma, Large-Cell Immunoblastic Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Advanced in Acute Monoblastic Leukemia (AmoL)
Dr. Kevin A. David
Oncology | Hematology
Advanced in Acute Monoblastic Leukemia (AmoL)
Dr. Kevin A. David
Oncology | Hematology

Memorial Sloan Kettering Cancer Center At Basking Ridge New Jersey

136 Mountainview Blvd, 
Basking Ridge, NJ 
 (56.3 miles away)
908-542-3000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Kevin David is an Oncologist and a Hematologist in Basking Ridge, New Jersey. Dr. David is rated as a Distinguished provider by MediFind in the treatment of Acute Monoblastic Leukemia (AmoL). His top areas of expertise are Non-Hodgkin Lymphoma, Hodgkin Lymphoma, B-Cell Lymphoma, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. David is currently accepting new patients.

VIEW MORE ACUTE MONOBLASTIC LEUKEMIA (AMOL) DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kasner's expertise for a condition
ConditionClose
  • Elite
  • Acute Myeloid Leukemia (AML)
    Dr. Kasner is
    Elite
    . Learn about Acute Myeloid Leukemia (AML).
    See more Acute Myeloid Leukemia (AML) experts
  • Distinguished
  • Acute Myeloblastic Leukemia with Maturation
    Dr. Kasner is
    Distinguished
    . Learn about Acute Myeloblastic Leukemia with Maturation.
    See more Acute Myeloblastic Leukemia with Maturation experts
  • Acute Myeloblastic Leukemia without Maturation
    Dr. Kasner is
    Distinguished
    . Learn about Acute Myeloblastic Leukemia without Maturation.
    See more Acute Myeloblastic Leukemia without Maturation experts
  • Childhood Acute Myeloid Leukemia
    Dr. Kasner is
    Distinguished
    . Learn about Childhood Acute Myeloid Leukemia.
    See more Childhood Acute Myeloid Leukemia experts
  • Myelodysplastic Syndrome (MDS)
    Dr. Kasner is
    Distinguished
    . Learn about Myelodysplastic Syndrome (MDS).
    See more Myelodysplastic Syndrome (MDS) experts
  • Non-Hodgkin Lymphoma
    Dr. Kasner is
    Distinguished
    . Learn about Non-Hodgkin Lymphoma.
    See more Non-Hodgkin Lymphoma experts
  • Advanced
  • Acute Lymphoblastic Leukemia (ALL)
    Dr. Kasner is
    Advanced
    . Learn about Acute Lymphoblastic Leukemia (ALL).
    See more Acute Lymphoblastic Leukemia (ALL) experts
  • Acute Megakaryoblastic Leukemia
    Dr. Kasner is
    Advanced
    . Learn about Acute Megakaryoblastic Leukemia.
    See more Acute Megakaryoblastic Leukemia experts
  • Acute Monoblastic Leukemia (AmoL)
    Dr. Kasner is
    Advanced
    . Learn about Acute Monoblastic Leukemia (AmoL).
    See more Acute Monoblastic Leukemia (AmoL) experts
  • Acute Myelomonocytic Leukemia
    Dr. Kasner is
    Advanced
    . Learn about Acute Myelomonocytic Leukemia.
    See more Acute Myelomonocytic Leukemia experts
  • Acute Promyelocytic Leukemia
    Dr. Kasner is
    Advanced
    . Learn about Acute Promyelocytic Leukemia.
    See more Acute Promyelocytic Leukemia experts
  • Aleukemic Leukemia Cutis (ALC)
    Dr. Kasner is
    Advanced
    . Learn about Aleukemic Leukemia Cutis (ALC).
    See more Aleukemic Leukemia Cutis (ALC) experts
View All 13 Advanced Conditions
  • Experienced
  • Agranulocytosis
    Dr. Kasner is
    Experienced
    . Learn about Agranulocytosis.
    See more Agranulocytosis experts
  • Anemia
    Dr. Kasner is
    Experienced
    . Learn about Anemia.
    See more Anemia experts
  • Aplastic Anemia
    Dr. Kasner is
    Experienced
    . Learn about Aplastic Anemia.
    See more Aplastic Anemia experts
  • B-Cell Lymphoma
    Dr. Kasner is
    Experienced
    . Learn about B-Cell Lymphoma.
    See more B-Cell Lymphoma experts
  • Burkitt Lymphoma
    Dr. Kasner is
    Experienced
    . Learn about Burkitt Lymphoma.
    See more Burkitt Lymphoma experts
  • Chronic B-Cell Leukemia (CBCL)
    Dr. Kasner is
    Experienced
    . Learn about Chronic B-Cell Leukemia (CBCL).
    See more Chronic B-Cell Leukemia (CBCL) experts
View All 31 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2026 All Rights Reserved

    Request an Appointment

    If you are experiencing a medical emergency, call 9-1-1.

    MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

    Patient Details

    This information is for the patient who will be seen at the appointment.

      Close

      Returning patient? Use your address on file with the provider.

      Insurance Details

      Please provide information of the primary insurance holder as the practice may require this information to schedule.

      Insurance Provider *
      Insurance ProviderClose

      Appointments Details

      Let’s get more information about your appointment.

              0 / 1000
              0 / 1000
              By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.